US · INBX
Inhibrx Biosciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- La Jolla, CA 92037
- Website
- inhibrx.com
Price · as of 2024-12-31
$128.79
Market cap 1.08B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $348.06 | +170.25% |
| Intrinsic Value(DCF) | $5.43 | -95.78% |
| Graham-Dodd Method(GD) | $592.12 | +359.75% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $0.00 | $73.87 | |||
| 2022 | $0.00 | $210.23 | |||
| 2023 | $0.00 | $45.56 | |||
| 2024 | $13.58 | $348.06 | $0.00 | $592.12 | $0.00 |
AI valuation
Our deep-learning model estimates Inhibrx Biosciences, Inc.'s (INBX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $348.06
- Current price
- $128.79
- AI upside
- +170.25%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.43
-95.78% upside
Graham-Dodd
$592.12
+359.75% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| INBX | Inhibrx Biosciences, Inc. | $128.79 | 1.08B | +170% | -96% | +360% | — | 0.12 | 1.47 | 982.91 | 0.03 | — | 1.47 | -1042.50% | -165724.00% | 843786.00% | 1905.92% | 1880.87% | 690.69% | 0.06 | -24.57 | 3.94 | 3.76 | -0.08 | -237695.00% | -8889.00% | -45.00% | -100.22% | -4.77 | 1117.95% | 0.00% | 0.00% | 39.05% | -0.16 | -0.26 | 260.17 | -3.58 |
| AMLX | Amylyx Pharmaceuticals, I… | $15.17 | 1.26B | +1,990% | -90% | — | +1,813% | -0.87 | 1.60 | 3.02 | -0.31 | — | 1.60 | 51.75% | -360.22% | -345.36% | -100.88% | -1111.62% | -84.87% | 0.01 | — | 6.67 | 6.23 | 0.26 | -73286.00% | -7706.00% | -167149.00% | -63.63% | -5.90 | -593.45% | 0.00% | 0.00% | 0.00% | -0.28 | -0.53 | 1.02 | -2.82 |
| ATAI | Atai Beckley N.V | $3.63 | 684.71M | +564% | -83% | — | — | -1.61 | 2.08 | 785.20 | -1.41 | -0.59 | 2.15 | 100.00% | -33341.23% | -48463.96% | -83.53% | -126.85% | -66.27% | 0.21 | -32.87 | 3.21 | 2.55 | -0.05 | 27200.00% | -191.00% | -257.00% | -34.13% | -3.30 | -102.19% | 0.00% | 0.00% | 0.00% | -1.99 | -2.47 | 663.04 | -4.47 |
| CVAC | CureVac N.V. | $4.66 | 1.05B | +3,460% | -35% | +67% | +15,600% | 3.05 | 0.84 | 1.09 | 0.65 | — | 0.87 | 80.23% | 33.20% | 30.30% | 31.46% | 74.77% | 23.99% | 0.06 | — | 7.28 | 7.16 | -2.11 | -16102.00% | 89554.00% | -12582.00% | 14.31% | 1.41 | 41.31% | 0.00% | 0.00% | 14.10% | 0.77 | 1.64 | 0.25 | 2.92 |
| ELVN | Enliven Therapeutics, Inc… | $29.69 | 1.76B | — | — | — | — | -11.10 | 3.19 | — | -6.48 | — | 3.19 | 0.00% | — | — | -32.04% | 1991.13% | -29.79% | 0.00 | — | 19.99 | 19.69 | 1.19 | -597.00% | — | 1924.00% | -7.41% | -4.60 | 1394.71% | 0.00% | 0.00% | 2.46% | -6.46 | -9.22 | — | 36.28 |
| IMTX | Immatics N.V. | $10.34 | 1.39B | +1,496% | -51% | -32% | +199% | 28.44 | 0.75 | 2.78 | -4.51 | — | 0.76 | 100.00% | -24.78% | 9.77% | 3.80% | 27.69% | 2.52% | 0.03 | -43.58 | 9.26 | 8.99 | -6.40 | -11167.00% | 18860.00% | 127096.00% | -40.32% | -2.32 | 175.55% | 0.00% | 0.00% | 4.04% | 4.03 | 0.89 | -1.00 | 1.96 |
| NKTR | Nektar Therapeutics | $68.98 | 1.4B | -92% | -92% | — | — | -1.52 | 2.98 | 1.84 | -0.33 | — | 2.98 | 68.82% | -106.88% | -120.86% | -124.10% | 143.06% | -33.90% | 1.69 | -3.74 | 4.26 | 4.18 | -0.67 | -6017.00% | 922.00% | -842.00% | -97.90% | -2.86 | 241.42% | 0.00% | 0.00% | 15.02% | -0.27 | -0.16 | 0.29 | -16.15 |
| ORIC | ORIC Pharmaceuticals, Inc… | $13.45 | 1.31B | — | — | — | — | -9.41 | 3.17 | — | -7.40 | — | 3.17 | 0.00% | — | — | -41.27% | -272.98% | -37.79% | 0.03 | — | 14.13 | 13.79 | 0.27 | -1967.00% | — | 20.00% | -9.36% | -5.55 | -217.77% | 0.00% | 0.00% | 0.00% | -6.63 | -8.32 | — | 24.72 |
| RLAY | Relay Therapeutics, Inc. | $10.26 | 1.78B | +180% | -62% | — | — | -6.08 | 2.96 | 109.40 | -5.44 | — | 2.96 | 76.83% | -1971.59% | -1800.58% | -41.12% | -108.03% | -37.05% | 0.06 | — | 22.61 | 3.28 | 0.17 | -3178.00% | 5344.00% | -608.00% | -14.04% | -9.21 | -84.17% | 0.00% | 0.00% | 0.06% | -5.38 | -6.90 | 106.04 | 13.52 |
| SANA | Sana Biotechnology, Inc. | $4.21 | 1.12B | — | — | — | — | -2.23 | 2.38 | — | -2.10 | — | 11.75 | 0.00% | — | — | -99.17% | -144.07% | -50.03% | 0.38 | — | 3.54 | 3.36 | 0.13 | -2055.00% | — | -622.00% | -43.07% | -4.91 | -135.54% | 0.00% | 0.00% | 0.66% | -1.97 | -2.09 | — | -4.58 |
| SNDX | Syndax Pharmaceuticals, I… | $21.71 | 1.89B | +262% | +64,186% | — | — | -6.72 | 29.67 | 11.13 | -6.06 | — | 29.67 | 95.96% | -158.45% | -165.60% | -161.82% | 196.12% | -45.50% | 0.00 | -8.08 | 4.40 | 3.60 | 0.54 | -1153.00% | 62784.00% | 1756.00% | -16.85% | -2.69 | 232.09% | 0.00% | 0.00% | 17.03% | -5.58 | -4.71 | 8.84 | -1.10 |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
- CEO
- Mark Paul Lappe
- Employees
- 156
- Beta
- 1.36
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.43 ÷ $128.79) − 1 = -95.78% (DCF, example).